Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease

Ruth Djaldetti, Eldad Melamed*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


In Parkinson's disease (PD), response fluctuations may be due, in part, to pharmacokinetic problems including poor solubility of levodopa and difficulties in its absorption. We administered levodopa ethylester (LDEE), a new highly soluble prodrug of levodopa, by subcutaneous and intramuscular injections to PD patients with response fluctuations, in an open trial to examine its safety and efficacy. Various doses of LDEE (150-400 mg) turned patients 'on' with a high success rate (43 of 45 injections). Latencies to 'turning on' decreased and duration of on responses increased in a dose- dependent manner. LDEE, given either subcutaneously or intramuscularly, produced similar beneficial effects and induced rapid and sustained elevations in plasma levodopa levels. The drug was well tolerated with only minor and negligible side effects. Study suggests that subcutaneous and intramuscular administration of LDEE may be advantageous as a novel therapeutic strategy for response fluctuations. It may be particularly useful to rapidly and predictably rescue patients from a variety of disabling 'off' situations.

Original languageEnglish
Pages (from-to)400-404
Number of pages5
JournalAnnals of Neurology
Issue number3
StatePublished - 1996


Dive into the research topics of 'Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease'. Together they form a unique fingerprint.

Cite this